IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC) - Finn, RS; Qin, S; Ikeda, M (Journal of Clinical Oncology, 2021)
et al.